Nasal polyps are soft, painless growths on the lining of your nasal passages or sinuses, often resulting from chronic ...

Nasal polyps are small noncancerous growths in the nose or sinuses. They may cause pain or pressure in the face, runny or stuffy nose, and other symptoms or complications that may negatively ...

Amgen (AMGN) and AstraZeneca's (AZN) asthma therapy Tezspire hits main goals in the Phase 3 trial for chronic rhinosinusitis ...

Amgen (NASDAQ:AMGN) and AstraZeneca today announced positive top-line results from the Phase 3 WAYPOINT trial in patients ...

Full results from the trial will be presented at an upcoming medical meeting. Topline results from a phase 3 trial show that tezepelumab statistically significantly reduced the size of nasal polyps ...

AstraZeneca has failed in its bid to get US approval for its IL-5 inhibitor Fasenra as a treatment for chronic rhinosinusitis in people with nasal polyps, after the FDA rejected its marketing ...

AstraZeneca PLC on Friday said it received positive results from a trial of Tezspire as a treatment for chronic rhinosinusitis with nasal polyps. Chronic rhinosinusitis is a disorder characterised by ...

Six months after Amgen and AstraZeneca reported promising results for Tezspire (t | A phase 3 study has shown that ...

Both trials met their co-primary endpoints of a change from baseline in total endoscopic nasal polyp score at 52 weeks and a change from baseline in mean nasal obstruction score from weeks 49 to 52.

Company continues to focus on upcoming results from ENLIGHTEN 2 pivotal Phase 3 trial in CRS patients expected in 2Q 2025 Company reports topline ...

The companies did not provide detailed data for Tezspire, however, and William Blair’s Matt Phipps said in a note he does not ...